Skip to main content

Table 1 Gene therapy vectors

From: Current trends in tendinopathy: consensus of the ESSKA basic science committee. Part II: treatment options

Class Main advantages Key limitations
Non-viral not infectious, not toxic low efficacy, short-term transgene expression
Adenoviral high efficacy immunogenic, short-term transgene expression
Retro−/lentiviral long-term transgene expression risk of insertional mutagenesis, restricted host-range, only for dividing cells (retroviral vectors), HIV-based material (lentiviral vectors)
rAAV high efficacy, long-term transgene expression, also for quiescent cells complex to prepare, size limitation